Why Is TWIST BIOSCIENCE COR (TWST) Stock Down Today?
By the Top Tier Newswire AI Desk · October 8, 2026 at 9:37 AM ET · reviewed against 4 wire stories
TWIST BIOSCIENCE COR (TWST) is down -5.68% in the latest session. Our newswire has captured 4 stories on TWST across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Twist Bioscience (TWST) shares declined 5.68% to $146.82, driven by a new analyst initiation that highlighted valuation concerns. Jefferies began coverage with a Hold rating, citing stretched multiples relative to near-term revenue growth. This move follows a broader pullback in the stock, which has lost 12.8% over the last eight sessions.
What Happened
Jefferies initiated coverage on Twist Bioscience with a Hold rating and a price target of $150. The firm noted that while the company benefits from AI drug discovery trends, the current valuation appears stretched given modest near-term revenue upside. In contrast, Barclays maintained its Overweight rating and raised its price target to $215 from $112. The stock opened at $152.49, representing a 2.0% gap down from the prior close of $155.65. Trading volume was light, with 0.3 million shares traded, which is 0.1 times the three-month daily average.
What The Data Shows
The company has a market capitalization of $10.5 billion and remains unprofitable, with a trailing twelve-month EPS of $2.23 and a net margin of 31.7%. Revenue grew 19.2% over the same period. The stock carries a high beta of 2.19, indicating elevated volatility relative to the broader market. Over the past 90 days, insiders have executed 37 sales totaling $119.8 million, with no recorded purchases. Recent filings include sales by CEO Emily M. Leproust on October 5, 2026, and SVP of HR Paula Green and President and COO Patrick John Finn on October 2, 2026. The 52-week range spans from $23.30 to $219.71. On October 8, 2026, the stock printed two fresh 52-week highs and three fresh 52-week lows.
What To Watch
Investors should monitor upcoming earnings reports for further insight into revenue trajectory and profitability. The divergence between Jefferies’ cautious stance and Barclays’ bullish price target suggests continued debate over the stock’s valuation. Additionally, the high level of insider selling may influence near-term sentiment as the stock consolidates after its recent decline.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Jefferies initiates Twist Bioscience stock at Hold on valuation
Jefferies initiates Twist Bioscience stock at Hold on valuation
1d agoThe FlyBULLISH 67Analyst
Twist Bioscience price target raised to $215 from $112 at Barclays
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →